Ambilip
Composition
LiposomalAmphotericin B 50mg Vial
Pharmaceutical form
VialsTherapeutic Indications
Treatment of Cryptococcal Meningitis in HIV infected patients.Treatment of patients with Aspergillus species, Candida species and/or Cryptococcus species infections refractory to amphotericin B deoxycholate.
In patients where renal impairment or unacceptable toxicity precludes the use of amphotericin B deoxycholate.
Treatment of visceral leishmaniasis, in immuno-compromised / immunocompetent patients.
Empirical therapy in febrile immunocompromised patients who do not respond to broad-spectrum antibiotics.
Posology and method of administration
For systemic mycosesa daily dose of 1 mg/kg/day of body weight, and
increased stepwise to 5.0mg/kg/day, as required.
For prophylaxis against invasive fungal
infections in liver transplant recipients
a daily dose of 1 mg/kg/day for five successive days
following transplantation.
In HIV-associated disseminated cryptococcosis
a dose of 3 mg/kg/day for up to 42 days.
In immunocompetent patients
a dose of 1 to 1.5 mg/kg/day for 21 days or
alternatively a dose of 3.0 mg/kg/day for 10 days
can be used for treatment of visceral leishmaniasis.
In immunocompromised patients (e.g., HIV
positive) with visceral leishmaniasis
a dose of 1 to 1.5mg/kg/day for 21 days may be used.
For empirical treatment of presumed fungal
infection of febrile neutropaenic patients
a daily dose of 1-3 mg/kg. The daily dosage may be
adjusted based on the clinical condition, as required.